CN114010628A - 紫杉烷颗粒及其用途 - Google Patents

紫杉烷颗粒及其用途 Download PDF

Info

Publication number
CN114010628A
CN114010628A CN202111091592.9A CN202111091592A CN114010628A CN 114010628 A CN114010628 A CN 114010628A CN 202111091592 A CN202111091592 A CN 202111091592A CN 114010628 A CN114010628 A CN 114010628A
Authority
CN
China
Prior art keywords
nozzle
particles
composition
paclitaxel
docetaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111091592.9A
Other languages
English (en)
Chinese (zh)
Inventor
M·巴尔特泽
J·法辛
J·西顿诺尔
J·埃斯皮诺萨
S·坎贝尔
M·麦克克罗雷
J·K·菲舍尔
M·D·威廉姆斯
G·E·克拉普
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CritiTech Inc
Original Assignee
CritiTech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CritiTech Inc filed Critical CritiTech Inc
Publication of CN114010628A publication Critical patent/CN114010628A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D46/00—Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D46/00—Filters or filtering processes specially modified for separating dispersed particles from gases or vapours
    • B01D46/24—Particle separators, e.g. dust precipitators, using rigid hollow filter bodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/08—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor
    • B01J19/10—Processes employing the direct application of electric or wave energy, or particle radiation; Apparatus therefor employing sonic or ultrasonic vibrations
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/26—Nozzle-type reactors, i.e. the distribution of the initial reactants within the reactor is effected by their introduction or injection through nozzles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/04—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a gaseous medium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/008—Processes carried out under supercritical conditions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J3/00—Processes of utilising sub-atmospheric or super-atmospheric pressure to effect chemical or physical change of matter; Apparatus therefor
    • B01J3/02—Feed or outlet devices therefor
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J4/00—Feed or outlet devices; Feed or outlet control devices
    • B01J4/001—Feed or outlet devices as such, e.g. feeding tubes
    • B01J4/002—Nozzle-type elements
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B05B1/341—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl before discharging the liquid or other fluent material, e.g. in a swirl chamber upstream the spray outlet
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B1/00—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means
    • B05B1/34—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl
    • B05B1/3405—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl
    • B05B1/341—Nozzles, spray heads or other outlets, with or without auxiliary devices such as valves, heating means designed to influence the nature of flow of the liquid or other fluent material, e.g. to produce swirl to produce swirl before discharging the liquid or other fluent material, e.g. in a swirl chamber upstream the spray outlet
    • B05B1/3489—Nozzles having concentric outlets
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B13/00—Machines or plants for applying liquids or other fluent materials to surfaces of objects or other work by spraying, not covered by groups B05B1/00 - B05B11/00
    • B05B13/02—Means for supporting work; Arrangement or mounting of spray heads; Adaptation or arrangement of means for feeding work
    • B05B13/0278—Arrangement or mounting of spray heads
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2271/00—Sealings for filters specially adapted for separating dispersed particles from gases or vapours
    • B01D2271/02—Gaskets, sealings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2204/00—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices
    • B01J2204/002—Aspects relating to feed or outlet devices; Regulating devices for feed or outlet devices the feeding side being of particular interest
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D—PROCESSES FOR APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05D2401/00—Form of the coating product, e.g. solution, water dispersion, powders or the like
    • B05D2401/90—Form of the coating product, e.g. solution, water dispersion, powders or the like at least one component of the composition being in supercritical state or close to supercritical state

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Filtering Of Dispersed Particles In Gases (AREA)
  • Glanulating (AREA)
  • Nozzles (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
CN202111091592.9A 2015-06-04 2016-06-06 紫杉烷颗粒及其用途 Pending CN114010628A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562171060P 2015-06-04 2015-06-04
US201562171008P 2015-06-04 2015-06-04
US201562171001P 2015-06-04 2015-06-04
US62/171,008 2015-06-04
US62/171,001 2015-06-04
US62/171,060 2015-06-04
CN201680032549.6A CN107683131B (zh) 2015-06-04 2016-06-06 紫杉烷颗粒及其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680032549.6A Division CN107683131B (zh) 2015-06-04 2016-06-06 紫杉烷颗粒及其用途

Publications (1)

Publication Number Publication Date
CN114010628A true CN114010628A (zh) 2022-02-08

Family

ID=56194575

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202111091592.9A Pending CN114010628A (zh) 2015-06-04 2016-06-06 紫杉烷颗粒及其用途
CN201680031730.5A Pending CN107743418A (zh) 2015-06-04 2016-06-06 收集装置及其使用方法
CN201680032291.XA Active CN107683174B (zh) 2015-06-04 2016-06-06 喷嘴组件及其使用方法
CN201680032549.6A Active CN107683131B (zh) 2015-06-04 2016-06-06 紫杉烷颗粒及其用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201680031730.5A Pending CN107743418A (zh) 2015-06-04 2016-06-06 收集装置及其使用方法
CN201680032291.XA Active CN107683174B (zh) 2015-06-04 2016-06-06 喷嘴组件及其使用方法
CN201680032549.6A Active CN107683131B (zh) 2015-06-04 2016-06-06 紫杉烷颗粒及其用途

Country Status (14)

Country Link
US (12) US9814685B2 (https=)
EP (4) EP3838264A1 (https=)
JP (5) JP6758325B2 (https=)
KR (5) KR20200134347A (https=)
CN (4) CN114010628A (https=)
AU (3) AU2016270558B2 (https=)
CA (3) CA3026454C (https=)
DK (1) DK3302431T3 (https=)
ES (1) ES2833749T3 (https=)
HK (1) HK1253021B (https=)
PT (1) PT3302431T (https=)
RU (1) RU2750163C2 (https=)
SG (2) SG10201913947RA (https=)
WO (3) WO2016197091A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3026454C (en) * 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
ES3055492T3 (en) 2015-09-16 2026-02-12 Dfb Soria Llc Delivery of drug nanoparticles and methods of use thereof
EP3854381A1 (en) 2016-04-04 2021-07-28 Crititech, Inc. Methods for solid tumor treatment
US11104073B2 (en) * 2016-05-12 2021-08-31 Hewlett-Packard Development Company, L.P. Build material container
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) * 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders
WO2019010316A1 (en) * 2017-07-07 2019-01-10 Dfb Pharmaceuticals, Llc TREATMENT OF HYPERPLASIC TISSUE GROWTH COMPRISING BENIGN PROSTATIC HYPERPLASIA (HBP) BY DIRECT INJECTION OF ANTINOPLASTIC AGENT
WO2019067851A1 (en) 2017-09-29 2019-04-04 Crititech, Inc. CIPROFLOXACIN POLYMORPHS AND USE THEREOF
WO2019067866A1 (en) 2017-09-29 2019-04-04 Crititech, Inc. GLUCOCORTICOID PARTICLES AND THEIR USE
KR20250057947A (ko) 2017-10-03 2025-04-29 크리티테크, 인크. 암의 치료를 위한 면역치료제의 전신 전달과 조합된 항신생물성 입자의 국소 전달
EP3735220A1 (en) * 2018-01-05 2020-11-11 Crititech, Inc. Treatment of bladder cancer by local administration of taxane particles
EP3765035A4 (en) * 2018-03-16 2021-10-27 DFB Soria, LLC TOPICAL THERAPY FOR THE TREATMENT OF CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN) AND COLD CANCER USING TAXANE NANOPARTICLES
US20190365699A1 (en) 2018-05-31 2019-12-05 Crititech, Inc. Treatment of Kidney Tumors by Intratumoral Injection of Taxane Particles
CA3093459A1 (en) 2018-05-31 2019-12-05 Crititech, Inc. Methods for isolating tumor-specific immune cells from a subject for adoptive cell therapy and cancer vaccines
WO2019231499A1 (en) 2018-05-31 2019-12-05 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for treatment of cancer
CN108970835B (zh) * 2018-09-20 2020-11-17 马鞍山纽泽科技服务有限公司 一种耐高温喷射装置
WO2020072090A1 (en) 2018-10-03 2020-04-09 Crititech, Inc. Use of antineoplastic agents to stimulate the immune system for production of tertiary lymphoid structures (tls)
US10732080B1 (en) * 2019-10-14 2020-08-04 Sotax Corporation Integrated dissolution processing and sample transfer system
US11911499B2 (en) 2019-11-07 2024-02-27 Resurge Therapeutics, Inc. System and method for prostate treatment
ES3037830T3 (en) * 2020-02-04 2025-10-07 Zhuhai Beihai Biotech Co Ltd Formulations of docetaxel
CN111238911A (zh) * 2020-02-10 2020-06-05 大连医科大学 一种断层塑化专用垂直包埋箱
US20220023215A1 (en) 2020-07-23 2022-01-27 Crititech, Inc. Lapatinib particles and uses thereof
US20230364021A1 (en) * 2020-07-23 2023-11-16 Crititech, Inc. Sorafenib particles and uses thereof
KR20230044422A (ko) * 2020-07-23 2023-04-04 크리티테크, 인크. 소라페닙 입자 및 이의 용도
JP2023541585A (ja) * 2020-09-08 2023-10-03 クリチテック，インコーポレイテッド ニクロサミド粒子およびその使用
EP4329778A4 (en) * 2021-04-26 2025-02-19 Crititech, Inc. CISPLATIN PARTICLES AND THEIR USES
CN113447635B (zh) * 2021-05-11 2023-09-29 江西农业大学 一种盆栽类土壤不同深度温室气体释放速率测定装置
JP2024543323A (ja) 2021-11-10 2024-11-21 クリチテック，インコーポレイテッド ルカパリブ粒子およびその使用
EP4429642B1 (en) 2021-11-10 2026-04-29 Crititech, Inc. Niraparib particles and uses thereof
US11602516B1 (en) 2022-01-29 2023-03-14 Resurge Therapeutics Inc. Treating benign prostatic hyperplasia
US11957654B2 (en) 2022-01-29 2024-04-16 Resurge Therapeutics, Inc. Treating benign prostatic hyperplasia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1592607A (zh) * 2001-10-15 2005-03-09 克里蒂泰克公司 水溶性差药物的组合物、其给药方法和治疗方法
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法

Family Cites Families (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3648698A (en) * 1969-05-23 1972-03-14 George O Doherty Surgical collection unit
DE3120047C2 (de) * 1981-05-20 1984-03-29 Sterimed Gesellschaft für medizinischen Bedarf mbH, 6600 Saarbrücken Sauggerät zum Ansaugen von Körpersekreten
JPS5958019U (ja) 1982-10-08 1984-04-16 松下電器産業株式会社 電気集塵機
US4780138A (en) * 1986-10-27 1988-10-25 Bodine Albert G Sonic apparatus and method for facilitating the extraction of minerals from ore in a leachant
US5143528A (en) * 1990-02-14 1992-09-01 Challenge Industries Lint collector
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US5409833A (en) * 1993-07-01 1995-04-25 Baxter International Inc. Microvessel cell isolation apparatus
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5480540A (en) 1994-10-17 1996-01-02 General Electric Company Spray apparatus for separating solids from fluids
US5874481A (en) 1995-06-07 1999-02-23 Alliance Pharmaceutical Corp. Fluorochemical solutions for the delivery of lipophilic pharmaceutical agents
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
WO1997031691A1 (en) * 1996-03-01 1997-09-04 The University Of Kansas Methods and apparatus for particle precipitation and coating using near-critical and supercritical antisolvents
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
AU741439B2 (en) 1996-12-30 2001-11-29 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
PT1023050E (pt) 1997-06-27 2013-12-04 Abraxis Bioscience Llc Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JPH11189403A (ja) * 1997-12-25 1999-07-13 Tic:Kk 層構造型複合粒子製造装置
JP3418751B2 (ja) 1998-01-22 2003-06-23 参天製薬株式会社 フルオロメトロン懸濁型点眼剤
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6221153B1 (en) 1998-06-09 2001-04-24 Trevor Percival Castor Method for producing large crystals of complex molecules
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6113795A (en) 1998-11-17 2000-09-05 The University Of Kansas Process and apparatus for size selective separation of micro- and nano-particles
PT1131063E (pt) 1998-11-25 2003-08-29 Universitaetsklinikum Freiburg Pomada ou creme de hiperforina
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
US7217735B1 (en) 1999-04-09 2007-05-15 Au Jessie L-S Methods and compositions for enhancing delivery of therapeutic agents to tissues
NZ516083A (en) * 1999-05-27 2003-08-29 Acusphere Inc Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US6616849B1 (en) 1999-08-25 2003-09-09 Shimadzu Corporation Method of and system for continuously processing liquid materials, and the product processed thereby
CA2388844A1 (en) 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
SE515604C2 (sv) * 2000-04-28 2001-09-10 Bst Ab Förfarande och anordning för uppsugning och transport av vätskor, företrädesvis blod
US6620351B2 (en) 2000-05-24 2003-09-16 Auburn University Method of forming nanoparticles and microparticles of controllable size using supercritical fluids with enhanced mass transfer
US6562952B1 (en) 2000-10-31 2003-05-13 The University Of Kansas Precipitation of proteins from organic solutions
US20020081339A1 (en) 2000-12-22 2002-06-27 Philippe Menei Treatment of inoperable tumors by stereotactic injection of microspheres
JP2004529934A (ja) 2001-05-01 2004-09-30 アンジオテック ファーマシューティカルズ，インコーポレイテッド 抗微小管剤およびポリペプチドまたはポリサッカリドを含む組成物、ならびに炎症状態を処置するための医薬品の調製のためのそれらの組成物の使用
EP1401563B2 (en) 2001-07-02 2015-09-16 Micro & Nano Materials SAGL Process for the production of micro and/or nano particles
TW586963B (en) * 2001-07-20 2004-05-11 Nektar Therapeutics Uk Ltd Method and apparatus for preparing target substance in particulate form and fluid inlet assembly for said apparatus
US20030054042A1 (en) 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
JP2005511629A (ja) 2001-11-20 2005-04-28 アドバンスト インハレーション リサーチ，インコーポレイテッド 持続作用生成物送達用組成物
JP2005519129A (ja) 2002-03-05 2005-06-30 クリーブランド ステート ユニバーシティー エアロゾル薬物送達のための凝集粒子
JP2003251127A (ja) * 2002-03-06 2003-09-09 Kazuo Hirakawa 集塵装置
WO2003080027A1 (en) 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003090715A2 (en) * 2002-04-25 2003-11-06 Nektar Therapeutics Uk Ltd Particulate materials
JP2005529127A (ja) 2002-04-26 2005-09-29 テバ ファーマシューティカル インダストリーズ リミティド 腫瘍内送達のためのミクロ粒子製薬組成物
US9339459B2 (en) * 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
CN1255394C (zh) 2002-06-24 2006-05-10 成都思摩纳米技术有限公司 紫杉醇纳米微粒的制备方法及应用
KR100573289B1 (ko) 2002-07-20 2006-04-24 대화제약 주식회사 방광내 투여를 통한 방광암치료용 파클리탁셀 조성물 및그의 제조 방법
US6916389B2 (en) * 2002-08-13 2005-07-12 Nanotechnologies, Inc. Process for mixing particulates
CN2578811Y (zh) * 2002-10-24 2003-10-08 陆纪清 全闭式煤粉取样装置
WO2004098570A1 (en) * 2002-10-30 2004-11-18 Spherics, Inc. Nanoparticulate bioactive agents
KR100508518B1 (ko) * 2002-11-13 2005-08-17 한미약품 주식회사 초임계유체 공정을 이용한 파클리탁셀 고체분산체의 제조방법 및 이 방법으로 제조된 파클리탁셀 고체분산체
CA2509365C (en) 2002-12-09 2012-08-07 American Bioscience, Inc. Compositions and methods of delivery of pharmacological agents
US7455797B2 (en) 2003-02-28 2008-11-25 Ferro Corporation Method and apparatus for producing particles using supercritical fluid
JP4927535B2 (ja) 2003-04-03 2012-05-09 ジェシー エル エス オウ 腫瘍を標的指向化する薬物を封入した粒子
US20060147535A1 (en) 2003-04-16 2006-07-06 Poongunran Muthukumaran Methods for and compositions of anticancer medicaments
US20050059613A1 (en) 2003-07-08 2005-03-17 Bahram Memarzadeh Compositions and methods for the enhanced uptake of therapeutic agents through the bladder epithelium
US8021831B2 (en) 2003-08-25 2011-09-20 Board Of Regents, The University Of Texas System Taxane chemosensitivity prediction test
JP2007001865A (ja) 2003-09-16 2007-01-11 Ltt Bio-Pharma Co Ltd 脂溶性薬物封入微粒子、その製造法およびそれを含有する製剤
WO2005039533A1 (en) 2003-10-15 2005-05-06 Medigene Ag Method of administering cationic liposomes comprising an active drug
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
WO2005042219A1 (en) 2003-10-24 2005-05-12 Ferro Corporation Method of forming particles
EP1686962B9 (en) 2003-11-05 2012-10-03 Elan Pharma International Limited Nanoparticulate compositions having a peptide as a surface stabilizer
DE10357091A1 (de) 2003-12-06 2005-07-07 Degussa Ag Vorrichtung und Verfahren zur Abscheidung feinster Partikel aus der Gasphase
GB0402963D0 (en) 2004-02-11 2004-03-17 Univ Nottingham Counter current mixing device for two different fluids
US8043631B2 (en) 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
US7833444B2 (en) 2004-10-29 2010-11-16 Nara Machinery Co., Ltd. Fine particle granulation method
JP2008523151A (ja) 2004-12-14 2008-07-03 トランセイブ， インク． 生理活性物質を含む脂質粒子、その調製法及び使用法
ES2265262B1 (es) 2005-01-31 2008-03-01 Activery Biotech, S.L.(Titular Al 50%) Procedimiento para la obtencion de sistemas micro- y nanodispersos.
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
JP2008531591A (ja) 2005-02-24 2008-08-14 エラン・ファルマ・インターナショナル・リミテッド ドセタキセルおよびそれらの類似体のナノ粒子製剤
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8118795B2 (en) * 2005-03-22 2012-02-21 Medindica-Pak, Inc Disposal chain supply systems method and apparatus
WO2006103112A2 (en) 2005-03-31 2006-10-05 Lidds Ab Method for treating prostate diseases based on local delivery of active substances
CN1923189A (zh) 2005-08-30 2007-03-07 孔庆忠 一种紫杉碱类抗癌药物的缓释注射剂
EP3527202A1 (en) 2005-08-31 2019-08-21 Abraxis BioScience, LLC Compositions and methods for preparation of poorly water soluble drugs with increased stability
JP2009518167A (ja) 2005-12-11 2009-05-07 エスセーエフ テクノロジーズ アクティーゼルスカブ ナノサイズ材料の製造
US8906392B2 (en) * 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CN101336899A (zh) 2006-01-25 2009-01-07 济南帅华医药科技有限公司 含紫杉烷的抗癌缓释注射剂
ATE460154T1 (de) 2006-03-14 2010-03-15 Lidds Ab Bioresorbierbare zusammensetzung mit kontrollierter freisetzung
US7964029B2 (en) * 2006-07-17 2011-06-21 Thar Instrument, Inc. Process flowstream collection system
CN101547814B (zh) 2006-10-11 2011-11-09 雷诺卡车公司 设有被动式无钥匙进入系统的卡车
US7744923B2 (en) 2006-10-11 2010-06-29 Crititech, Inc. Method for precipitation of small medicament particles into use containers
TWI405590B (zh) * 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
US20100166869A1 (en) 2007-05-03 2010-07-01 Desai Neil P Methods and compositions for treating pulmonary hypertension
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
CN101129338A (zh) * 2007-08-27 2008-02-27 四川大学 超临界流体新技术微细化抗癌药物紫杉醇
WO2009111271A1 (en) 2008-03-06 2009-09-11 Nitto Denko Corporation Polymer paclitaxel conjugates and methods for treating cancer
WO2009119055A1 (ja) 2008-03-24 2009-10-01 三洋化成工業株式会社 樹脂粒子及びその製造方法
EP2345426B1 (en) 2008-09-19 2014-03-05 Activus Pharma Co., Ltd. Composite organic compound powder for medical use, method for producing same and suspension of same
EP3181123A1 (en) 2008-12-02 2017-06-21 Biocompatibles Uk Ltd. Pancreatic tumour treatment
PT104693B (pt) 2009-07-27 2011-11-24 Univ Lisboa Nanopartículas lipídicas semi-sólidas contendo um agente antineoplásico e seu processo de preparação
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
US20110209578A1 (en) * 2010-02-26 2011-09-01 Kuniaki Ara Nanoparticle manufacturing device and nanoparticle manufacturing method and method of manufacturing nanoparticle-dispersed liquid alkali metal
CA2801314A1 (en) 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer
US9339554B2 (en) 2010-09-21 2016-05-17 Cristal Delivery B.V. Tunable, biodegradable linker molecules for transient conjugation of components in drug delivery systems, and drug delivery systems prepared therewith
US20150093440A1 (en) 2010-10-15 2015-04-02 Glaxo Group Limited Aggregate nanoparticulate medicament formulations, manufacture and use thereof
BR112013010575A2 (pt) * 2010-10-29 2016-08-09 Velico Medical Inc conjunto de secagem por atomização, câmara de secagem por atomização, conjunto de cabeça de secagem por atomização, dispositivo de coleta de secagem por atomização, e, método para secar por atomização um líquido
WO2012096995A2 (en) * 2011-01-11 2012-07-19 Boston Scientific Scimed, Inc. Coated medical devices
KR20140022904A (ko) 2011-04-20 2014-02-25 유니버시티 오브 시드니 치료방법 및 그에 사용가능한 제제
US20140154269A1 (en) 2011-04-26 2014-06-05 The Methodist Hospital Research Institute Targeted nanovectors and their use for treatment of brain tumors
EP2720680B1 (en) 2011-06-17 2020-02-12 Berg LLC Inhalable pharmaceutical compositions
BR112013033466A8 (pt) 2011-06-27 2018-03-06 Cristal Delivery B V uso de um sistema de liberação controlada e sistema de liberação controlada
US11766459B2 (en) * 2011-07-08 2023-09-26 Jointechlabs, Inc. System and methods for preparation of adipose-derived stem cells
PT2750789T (pt) * 2011-08-31 2018-10-30 Archer Daniels Midland Co Processo de oxidação em spray para produzir ácido 2,5- furandicarboxílico a partir de hidroxi-metilfurfural
FR2980683B1 (fr) 2011-09-30 2014-11-21 Univ Paris Curie Dispositif de guidage d'un instrument medical insere dans une voie naturelle ou une voie artificielle d'un patient
CN102319898B (zh) * 2011-10-13 2013-05-08 西北工业大学 一种制备合金及金属基复合材料零部件的喷射成形系统
CN102488682A (zh) 2011-11-22 2012-06-13 四川九章生物化工科技发展有限公司 绿原酸的抗癌新用途
JP2013212494A (ja) * 2012-03-05 2013-10-17 Ricoh Co Ltd 樹脂微粒子の製造方法
WO2013166487A1 (en) 2012-05-04 2013-11-07 Yale University Highly penetrative nanocarriers for treatment of cns disease
CN102728414A (zh) * 2012-07-07 2012-10-17 中山大学 用于制备单壁碳纳米管的催化剂的制备方法及其运用
TW201408304A (zh) 2012-08-31 2014-03-01 Cathay General Hospital 一種合併抗癌藥物及荷爾蒙之抗腎細胞癌藥物及其製造方法
PL2897620T3 (pl) 2012-09-21 2020-11-02 Intensity Therapeutics, Inc Sposób leczenia nowotworu złośliwego
US9132363B2 (en) * 2012-11-20 2015-09-15 Apeks Llc Extraction system
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
NZ709958A (en) 2013-02-28 2018-03-23 Pfizer Enhanced stability of novel liquid compositions
US8778181B1 (en) * 2013-03-14 2014-07-15 Crititech, Inc. Equipment assembly for and method of processing particles
US9925512B2 (en) 2013-03-14 2018-03-27 Crititech, Inc. Equipment assembly for and method of processing particles
EP2978420A4 (en) 2013-03-28 2016-12-21 Bbs Nanotechnology Ltd STABLE NANO COMPOSITION WITH DOXORUBICIN, PROCESS FOR THE PREPARATION THEREOF, THE USE THEREOF AND PHARMACEUTICAL COMPOSITIONS THEREWITH
WO2014169137A1 (en) 2013-04-10 2014-10-16 Massachusetts Institute Of Technology Local drug delivery devices and methods for treating cancer
CN203699094U (zh) * 2013-10-15 2014-07-09 雷海平 新式垃圾桶及配套内桶
US10188738B2 (en) 2013-10-16 2019-01-29 Université Libre de Bruxelles Formulations useful in the treatment of proliferative diseases affecting the respiratory tract
JP2017507900A (ja) 2013-12-17 2017-03-23 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
WO2015103005A1 (en) 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
CN203737192U (zh) * 2014-01-20 2014-07-30 四川西汉电子科技有限责任公司 一种造粒机
TWI601542B (zh) 2014-04-18 2017-10-11 林信湧 一種用於治療肺癌之吸入式醫藥組成物及其備製方法
US20150342872A1 (en) * 2014-06-01 2015-12-03 Crititech, Inc. Use of Paclitaxel Particles
CN203847940U (zh) * 2014-06-04 2014-09-24 刘希 一种加料喷嘴调节支架
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
US9533449B2 (en) * 2014-06-19 2017-01-03 Autodesk, Inc. Material deposition systems with four or more axes
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
CA3026454C (en) * 2015-06-04 2023-07-04 Crititech, Inc. Collection device and methods for use
ES3055492T3 (en) * 2015-09-16 2026-02-12 Dfb Soria Llc Delivery of drug nanoparticles and methods of use thereof
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
DE202016006620U1 (de) 2015-10-28 2017-04-12 Qass Gmbh Vorrichtungen zum Beobachten eines Magnetfelds eines Materialvolumens
SG11201805186VA (en) 2016-01-20 2018-07-30 Fate Therapeutics Inc Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3854381A1 (en) * 2016-04-04 2021-07-28 Crititech, Inc. Methods for solid tumor treatment
CN107281502B (zh) 2016-04-05 2021-05-04 上海市肿瘤研究所 一种复合显影温敏凝胶栓塞剂、制备方法及其应用
WO2017178585A1 (en) 2016-04-15 2017-10-19 Cellectis A method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
WO2017194139A1 (en) * 2016-05-12 2017-11-16 Hewlett-Packard Development Company, L.P. Build material container
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
WO2018045239A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
WO2018170207A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin keratoses using nanoparticles of taxanes
WO2018170210A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of vulvar intraepithelial neoplasia (vin) and genital warts using nanoparticles of taxanes
WO2018170196A1 (en) 2017-03-15 2018-09-20 Dfb Soria, Llc Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes
CA3063420A1 (en) 2017-06-09 2018-12-13 Crititech, Inc. Treatment of epithelial cysts by intracystic injection of antineoplastic particles
WO2018231908A1 (en) 2017-06-14 2018-12-20 Crititech, Inc. Methods for treating lung disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1592607A (zh) * 2001-10-15 2005-03-09 克里蒂泰克公司 水溶性差药物的组合物、其给药方法和治疗方法
CN101829061A (zh) * 2010-05-14 2010-09-15 无锡纳生生物科技有限公司 一种紫杉醇纳米颗粒组合物及其制备方法

Also Published As

Publication number Publication date
CN107683131B (zh) 2021-09-28
US20160374953A1 (en) 2016-12-29
AU2016270549A1 (en) 2017-11-16
JP6758325B2 (ja) 2020-09-23
EP3302780A1 (en) 2018-04-11
JP2020203913A (ja) 2020-12-24
JP6921759B2 (ja) 2021-08-18
DK3302431T3 (da) 2020-11-30
CA3026452C (en) 2023-03-21
US20210393569A1 (en) 2021-12-23
WO2016197101A1 (en) 2016-12-08
EP3302423B1 (en) 2022-05-25
US11291646B2 (en) 2022-04-05
JP6892394B2 (ja) 2021-06-23
US20170224650A1 (en) 2017-08-10
EP3302431A1 (en) 2018-04-11
AU2016270558B2 (en) 2020-08-13
JP2022121532A (ja) 2022-08-19
JP2018524145A (ja) 2018-08-30
EP3302431B1 (en) 2020-11-11
SG10201913947RA (en) 2020-03-30
SG10201913945QA (en) 2020-03-30
JP2018526188A (ja) 2018-09-13
EP3302780B1 (en) 2019-04-17
AU2016270559B2 (en) 2020-12-10
RU2750163C2 (ru) 2021-06-22
CA3026452A1 (en) 2016-12-08
HK1253018A1 (en) 2019-06-06
CA3026454C (en) 2023-07-04
EP3838264A1 (en) 2021-06-23
RU2017140678A3 (https=) 2019-07-17
CA3026454A1 (en) 2016-12-08
AU2016270559A1 (en) 2017-11-16
KR102551708B1 (ko) 2023-07-06
US20200163928A1 (en) 2020-05-28
KR20200020995A (ko) 2020-02-26
US9814685B2 (en) 2017-11-14
CN107743418A (zh) 2018-02-27
CN107683174B (zh) 2021-02-19
CN107683131A (zh) 2018-02-09
US11123322B2 (en) 2021-09-21
AU2016270549B2 (en) 2019-01-17
US20180125783A1 (en) 2018-05-10
WO2016197091A1 (en) 2016-12-08
HK1253020A1 (en) 2019-06-06
ES2833749T3 (es) 2021-06-15
US20160354336A1 (en) 2016-12-08
KR20180016366A (ko) 2018-02-14
EP3302423A1 (en) 2018-04-11
HK1253021B (en) 2020-01-24
KR20180015635A (ko) 2018-02-13
WO2016197100A1 (en) 2016-12-08
US20210000786A1 (en) 2021-01-07
JP2018516907A (ja) 2018-06-28
JP7096299B2 (ja) 2022-07-05
RU2017140678A (ru) 2019-07-09
HK1253021A1 (en) 2019-06-06
BR112017025815A2 (pt) 2018-08-14
US20200101039A1 (en) 2020-04-02
KR20200134347A (ko) 2020-12-01
KR102317107B1 (ko) 2021-10-25
US20180116910A1 (en) 2018-05-03
CN107683174A (zh) 2018-02-09
CA2988132C (en) 2021-04-27
US20200405684A1 (en) 2020-12-31
US20180169058A1 (en) 2018-06-21
KR102077518B1 (ko) 2020-02-14
US10729673B2 (en) 2020-08-04
US10993927B2 (en) 2021-05-04
AU2016270558A1 (en) 2017-11-16
CA2988132A1 (en) 2016-12-08
US10751319B2 (en) 2020-08-25
PT3302431T (pt) 2020-11-30
US10507195B2 (en) 2019-12-17
KR102337080B1 (ko) 2021-12-08
KR20180013906A (ko) 2018-02-07
US20250186390A1 (en) 2025-06-12
US9918957B2 (en) 2018-03-20

Similar Documents

Publication Publication Date Title
CN107683131B (zh) 紫杉烷颗粒及其用途
HK40056120A (en) Taxane particles and their use
US11738029B2 (en) Rucaparib particles and uses thereof
HK1253018B (en) Taxane particles and their use
BR112017025815B1 (pt) Partículas de taxano, composições compreendendo as partículas de taxano, uso da composição compreendendo as partículas de taxano e métodos de fabricação das partículas de taxano
CN118103031A (zh) 尼拉帕尼颗粒及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination